Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab for bullous pemphigoid
2026-525685-22-00Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lebrikizumab in Bullous Pemphigoid (BP), sponsored by Central Denmark Region. Primary endpoint: Change in Bullous Pemphigoid Disease Area Index. Planned start Aug 2026; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2026-525685-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525685-22-00.